Schwannomas are benign tumors composed of dedifferentiated Schwann cells that form along peripheral nerves causing nerve compression often associated with pain and loss of function. Current surgical therapy involves total or subtotal surgical removal of the tumor, which may cause permanent nerve damage. In the present study, we explore an alternate means of therapy in which schwannomas are injected with a replication-conditional herpes simplex virus (HSV) vector to shrink the tumor through cell lysis during virus propagation. The oncolytic vector used, G47D, has deletions in HSV genes, which allow it to replicate selectively in dividing cells, sparing neurons. Two schwannoma cell lines were used to generate subcutaneous tumors in nude mice: HEI193, an immortalized human line previously established from an NF2 patient and NF2S-1, a newly generated spontaneous mouse line. Subcutaneous HEI193 tumors grew about ten times as fast as NF2S-1 tumors, and both regressed substantially following injection of G47D. Complete regression of HEI193 tumors was achieved in most animals, whereas all NF2S-1 tumors resumed growth within 2 weeks after vector injection. These studies provide a new schwannoma model for testing therapeutic strategies and demonstrate that oncolytic HSV vectors can be successfully used to shrink growing schwannomas.
Introduction
Schwannomas arise through unregulated overgrowth of Schwann cells, which normally serve to form a protective sheath around peripheral nerves. 1, 2 Schwannomas can arise during development, as Schwann cells move out along axons and begin myelination, or later in life when Schwann cells dedifferentiate and commence proliferation in response to nerve injury. 3 In fact, Schwann cells in damaged nerves share many features with Schwann cells in development. 4 Although schwannomas are almost always benign, they cause clinical symptoms by continued growth and nerve compression. Schwannomas typically result from loss of the neurofibromatosis 2 tumor suppressor gene (NF2), but can also arise through other genetic mechanisms. In NF2, loss of one NF2 allele is hereditary, with the loss of the second, wild-type allele occurring as a somatic mutation. Other hereditary syndromes in which patients develop multiple schwannomas include schwannomatosis, of unidentified genetic etiology, 5 and Carney's complex caused by loss of the tumor suppressor gene encoding the R1 alpha regulatory subunit of protein kinase A. 6 Schwannomas may also occur in the absence of a hereditary syndrome owing to a localized somatic cell mutation of the NF2 gene. The NF2 gene-encoded protein, merlin or schwannomin, 7, 8 links the actin cytoskeleton with membrane proteins involved in signal transduction. 3 Schwannomas of the eighth vestibular nerve are often associated with hearing loss, whereas schwannomas of other cranial nerves or peripheral nerves may cause chronic pain, loss of sensation and paralysis. When schwannomas become very large, compression of adjacent structures, brain stem, spinal cord peripheral nerves and organs, may occur. 9 Particularly challenging to treat by surgery are cranial nerve schwannomas owing to potential brain stem or cranial damage. Although schwannomas can be life-threatening because of their size and location, these tumors are usually not malignant and, therefore, reductions in volume alone can be highly beneficial, as complete surgical resection is not always possible or may be associated with serious complications. Treatment strategies need to focus on reducing the size of schwannomas while sparing associated nerves.
One obstacle to the development of new therapeutic interventions for schwannomas is the lack of appropriate experimental animal models for convenient testing. Although several mouse models of NF2 schwannomas have been generated, these are limited by a long time interval to tumor formation, random location of tumors within the animals and the difficulty in assessing changes in tumor size over time in living animals. For example, two genetic mouse models have been developed by Dr Giovannini. Transgenic mice expressing a dominant mutant form of merlin (found in human patients) under control of the Schwann cell-specific P0 promoter develop multiple schwannomas and Schwann-cell hyperplasias. 10 However, these lesions can take over a year to form, and are in sporadic locations making it difficult to monitor growth by in vivo imaging and to access tumors for intervention. 11 An NF2 floxed mouse model has also been generated and characterized. 12 When homozygous Nf2 flox2/flox2 mice are crossed with transgenic mice bearing Cre under the P0 promoter, offspring develop both benign and malignant Schwann cell tumors from 10 months of age or later predominantly within the spinal ganglia, with lower frequency in peripheral nerves. Meningiomas can also be elicited in these Nf2 floxed mice by injection of adenovirus vectors encoding Cre into the neonatal mouse brain. 13 When these P0Cre Â Nf2 floxed mice are also hemizygous for the tumor suppressor p53, they develop multiple malignant peripheral nerve sheath tumors within the first 2 months of age.
14 These tumors are accessible, but again they occur in random locations and are not typical of most schwannomas found in human patients, and the mice die within a few months of age. Xenograft models have also been generated by implanting fragments of schwannoma tissue (surgical material from patients) subcutaneously into nude mice. 15 However, this method had very low yield with schwannoma tissues from only two patients out of 12 successfully giving rise to schwannoma xenografts, which showed consistent growth over a period of months (with a rate of growth similar to spontaneous lesions in NF2 transgenic mice). These tumors had the histological features of peripheral nerve sheath tumors and showed diffuse S100 immunopositivity. Finally, although tumor fragments could be placed in sites accessible to measurement and injection, they grew very slowly and in some cases elicited an inflammatory response over months even in nude mice. This led us to explore schwannoma cell lines, which could be grown in culture and implanted into nude mice with a high rate of tumor formation.
Therapeutic treatment of schwannomas typically involves surgical resection, which may result in permanent nerve damage. In a previous study, we found that schwannoma cells from Nf2 transgenic mice and human schwannoma xenograft implants are highly infectable with HSV vectors. 15 We used a recombinant, oncolytic vector, G47D, with mutations in viral genes that allow it to replicate selectively in tumor cells. 16, 17 G47D is deleted for gamma 34.5 genes and the ICP6 gene encoding the large subunit of ribonucleotide reductase (with insertion of the lacZ gene), both of which promote selective virus replication in tumor cells 18 as well as being deleted for the ICP47 gene, which is involved in blocking presentation of viral antigens through the major histocompatibility complex class I (MHC I) pathway. 19 This oncolytic virus was effective at reducing tumor size in both the Nf2 transgenic and human schwannoma xenograft models. 15 In the present study, we evaluate the ability of the oncolytic G47D virus to reduce effectively the size of subcutaneous tumors derived from two schwannoma cell lines; a human schwannoma line, HEI193, derived by Hung et al. 20 through immortalization of NF2 tumor cells in culture by infection with a retrovirus vector encoding human papilloma virus (HPV) E6-E7 genes, and a mouse schwannoma line, NF2S-1, generated in the present study by culturing cells from a tumor formed in nude mice at the site of implantation of a human schwannoma fragment from an NF2 patient. Both schwannoma cell lines expressed S100 and were highly infectable with G47D virus. Subcutaneous tumors formed by implantation of these cells in nude mice regressed substantially following injection of G47D, with complete regression seen for most HEI193 tumors.
Materials and methods

Cell culture
Human HEI193 schwannoma cells were obtained from the House Ear Institute. 20 Mouse NF2S-1 schwannoma cells were generated from a spontaneous tumor that formed in nu/nu mice (NCI), following subcutaneous implantation of mediastinal schwannoma tissue from an NF2 patient (as per the clinical diagnosis of the primary physician), which was resected at the time of clinically indicated surgery under IRB approval. Three months after implantation, a small tumor of about 3 mm 3 at the site of implantation was removed. Tumor dissociation was carried out overnight at 37 1C in 20 ml of L15 medium (Gibco, Grand Island, NY) with 1.25 U of dispase (Gibco)/ml, 0.05% collagenase (Sigma, St Louis, MO) and 50 mg/ml gentamicin (Gibco). Cells were collected by centrifugation and resuspended in Dulbecco's modified Eagle's medium (DMEM, Cellgro, Herndon, VA) containing serum-free N-2 Supplement (Gibco) with 2 mM forskolin (Calbiochem, San Diego, CA), 14 ng/ml of recombinant human glial growth factor (rhGGF2, Sigma), 50 mg/ml gentamicin, 10% fetal bovine serum (FBS, Sigma) and 100 mg/ml penicillin/streptomycin (P/S, Cellgro), and plated onto poly-L-lysine-coated dishes (35 mm). All cells were grown at 37 1C in a 95% air/5% CO 2 atmosphere.
For karyotyping, schwannoma cells were harvested and metaphase spreads were stained by Giemsa-TrypsinGiemsa banding and evaluated by the Dana Farber/ Harvard Cancer Center Cytogenetics Core Laboratory at Brigham and Women's Hospital.
Generation and propagation of G47D
G47D was propagated and titered as described in Todo et al. 19 Briefly, Vero cells were grown in DMEM with 10% FBS, P/S and 500 mg/ml G418 (Geneticin, Gibco) and infected with G47D at a multiplicity of infection (MOI) ¼ 0.02À0.03 plaque forming units (pfu)/cell for 90 min, then the viral inoculum was removed and DMEM containing 2% heat-inactivated FBS (Sigma) and 1:2000 human immunoglobin G (IgG) (BayGam/Bayer, Elkar, IN) was added. Two or 3 days later, when infected cells were rounded and refractile, they were harvested by centrifugation. Cell pellets were resuspended in a 1:1 mix of media and 150 mM NaCl/20 mM Tris (pH 7.5), and the cell suspension was lysed by three cycles of freezethawing. Following centrifugation (20 000 R.P.M., Beckman Centrifuge Rotor SW 28), progeny virus was titered on Vero cells, as described, 19 with typical titers of 2.5 Â 10 8 pfu/ml. To determine the burst size of viral progeny in schwannoma cells, HEI-193 and NF2S-1 cells were infected with G47D at approximately 1 pfu/cell and virus harvested and titered 1 day later. Cells were seeded into 12-well plates (1 Â 10 5 cells/well), infected at 70-80% confluency, and the inoculum removed after 2 h and replaced with media (DMEM/1% FBS). Cells and medium were harvested at the indicated times postinfection, processed with three freeze-thaw cycles, sonicated, and titered on Vero cells. Experiments were repeated at least three times for each line in duplicate.
Generation and treatment of tumors
For the establishment of schwannomas, 5 Â 10 6 cells, either HEI193 or NF2S-1 was suspended in 100 mlreduced serum media (Opti-MEM 1, Gibco), mixed with 100 ml of Matrigel (1:1 ratio; BD Matrigelt Matrix HC, BD Biosciences, Bedford, MA) and implanted subcutaneously into one flank of immunodeficient mice (nu/nu, NCI). When tumor growth was apparent (approximately 1 week after the injection), tumor volumes were measured once/twice a week with external calipers, and the volume was calculated as (4p/3)(width/2)2(length/2). 21 When the tumors reached a size of 100 mm 3 (baseline day 1) the animals were randomly divided into two groups of six animals each. One group was injected with 2 Â 10 7 pfu G47D diluted in 0.9% sodium chloride (1:3) (Abbott Laboratories, North Chicago, IL) in a total volume of 120 ml over 5 min on baseline day 7 and 13. A control group was injected with 120 ml PBS/saline (1:1) into each tumor at the same time points.
Histology and immunocytochemistry
Following treatment with G47D or vehicle, animals were killed under heavy anesthesia with ketamine (200 mg/kg)/ xylazine (50 mg/kg) mix followed by transcardial perfusion with ice cold 0.1 M PBS (pH 7.4), then 4% buffered paraformaldehyde in PBS. Tumors were harvested, postfixed overnight, transferred to 30% sucrose solution and stored at 4 1C until they sank. Samples were sectioned from a cryostat at 30 mm and mounted on charged, precleaned Probe-On Plus Microscope slides (Fisher Scientific, Pittsburgh, PA). Hematoxylin and eosin (H&E) staining was performed on tissue sections, as described previously.
11
For immunostaining of tissue sections, tissue was deparaffinized and hydrated, as described previously. Staining for S100 using a polyclonal rabbit anti-cow S100 antibody (Dako, Glostrun Denman, Carpinteria, CA) was performed, as described previously. 11 Parallel sections were stained with the rabbit anti-b-galactosidase polyclonal antibody (Chemicon International, Temecula, CA) diluted 1:200 in 1% goat serum and then applied to tissue sections overnight at 4 1C. Other parallel sections were stained with monoclonal mouse antibody to glial fibrillary acidic protein (GFAP, Dako, Carpintera, CA) diluted 1:1000 in 1% BSA and applied to tissue sections overnight at 4 1C. Following the primary antibody incubation, sections were washed 3 Â with PBS. The secondary goat anti-rabbit IgG-antibody (Alexa Fluor 594, Molecular Probes, Eugene, OR) for b-galactosidase stained slides was used at a dilution of 1:1500 and the secondary biotinylated horse anti-mouse antibody at a dilution of 1:2000 for 30 min at room temperature. Following incubation with the secondary antibody, sections were rinsed 3 Â in PBS and dehydrated through grades of alcohol before being mounted with glass coverslips and fluorescent mounting medium (Dako).
Results
Characterization of schwannoma cell lines
The human schwanomma cell line used in these studies, HEI193, was originally generated by infection with a retrovirus vector encoding the immortalizing genes E6-E7 from HPV and characterized by Hung et al. 20 The mouse schwannoma cell line, NF2S-1, was generated by injecting fragments of a schwannoma tumor from an NF2 patient subcutaneously into a nude mouse. When a tumor formed 3 months later (about 3 mm 3 in diameter) and the cells from it were placed in culture, they showed a mouse karyotype and a schwannoma phenotype. Both cell lines showed strong immunocytochemical staining for the Schwann cell marker S100 and both were highly infectable with G47D virus, which encodes lacZ (Figure 1 ). Properties of these two cell lines in culture are compared in Table 1 . Karyotypic analysis indicated a chromosomal number of 67 human chromosomes (in 10/10 metaphases examined) for HEI193 and 43 mouse chromosomes for NF2S-1 (in 9/10 metaphases with the other one having 44 chromosomes). The previously reported karyotype of HEI193 was a modal chromosome number of 37 with about 25% of cells being tetraploid (presumably about 92 chromosomes 20 ) , and thus, during passage in our laboratory, the chromosomal number has increased. The HEI193 cells grew twice as rapidly as NF2S-1 cells with generation times of 12 and 24 h, respectively. Both lines proved highly infectable with the HSV G47D virus infecting 490% of HEI193 and NF2S-1 cells at an MOI of 1 pfu/cell. G47D was able to propagate in both cell types to a limited extent, HEI193 cells produced on average 2.3 pfu/cell and NF2S-1 cells 0.9 pfu/cell at 24 h after infection at an MOI of 1.
Growth and treatment of schwannomas xenografts HEI193 and NF2S-1 cells were implanted subcutaneously into the flanks of nude mice with matrigel and tumor growth was evident after 1 week. Tumors were removed 25-35 days after implantation and histologically analyzed using H&E staining and GFAP immunostaining. The HEI193 human schwannoma was defined histologically as a poorly differentiated malignant tumor with a nodular growth pattern. Tumor cells were large and polymorphic and immunonegative for GFAP (Figure 2a Figures  3a and 5b) . When tumors reached 100 mm 3 in size, they were injected directly with vehicle or G47D vector (2 Â 10 7 pfu) at two successive times, after 5-7 days. Both tumors showed a progressive decrease in volume within 5-7 days after the first vector injection with a significant volume reduction starting at 2 weeks after the first virus injection (Figure 3a and b) . The rate of reduction of HEI193 tumors after the first injection was about 70 mm 3 / day (n ¼ 12; Figures 3a and 5a) to 15% of the volume at time of injection after 2 weeks, that for NF2S-1 tumors was about 20 mm 3 /day (n ¼ 12; Figures 3b and 5b) to 30% of volume at time of injection after 3 weeks. Both types of treated tumors, removed 2 weeks after the last virus injection, showed positive immunocytochemistry for S100 (Figure 4a and c) and some continuing virus replication as indicated by a few lacZ-positive cells within the tumor (Figure 4b and d) .
To determine whether G47D could eliminate tumors, subcutaneous HEI193 (Figure 5a ) and NF2S-1 (Figure 5b ) tumors were established and injected as above with vector when they reached a size of 100 mm 3 on successive days 7 and 10 (HEI193) or 14 and 21 (NF2S-1). Both types of G47D-treated tumors regressed in size. A paired t-test indicated HEI193 tumors were significantly smaller than uninjected tumors 10 days following initial virus injection (Po0.002) and NF2S-1 tumors were significantly smaller 21 days following the initial injection (Po0.02), at which point, they began to regrow. Interestingly, the more rapidly growing HEI193 tumors were more susceptible to the virus, and 38 days following the initial injection only scar tissue was found in the region of the tumor in 4/6 animals, whereas in the other two animals the tumor was still very small (one being 50 mm 3 and the other 90 mm 3 as measured with external calipers).
Discussion
Findings in this study
This represents the first successful attempt to generate schwannomas from cell lines in nude mice, with a critical factor being use of matrigel at the time of cell implantation. In addition to the immortalized human schwannoma line, HEI193 previously generated by Hung et al., 20 we have now characterized an induced mouse schwannoma line NF2S-1, which is syngeneic with the Swiss strain background of the nude mice in which it arose. The human schwannoma line grew more rapidly, both in culture and as an implant, compared to the NF2S-1 line, and both were positive for S100, consistent with Schwann cell origin. 22 The growth rate of the mouse schwannoma line was in the range of that observed for spontaneous tumors in the NF2 transgenic model, 15 whereas the human schwannoma grew at a 10-fold faster rate. This Figure 3 Growth of schwannoma tumors and response to G47D. HEI193 (a) and NF2S-1 (b) tumors were grown subcutaneously in nude mice (n ¼ 6/group). When they reached a volume of 100 mm may reflect varying growth rate and range seen in NF2-associated human schwannomas, although such rapid growth is unusual in human schwannomas. As previously shown for spontaneous schwannomas in NF2 transgenic mice and human schwannoma tissue implants, 15 both schwannoma cell lines were highly infectable with the oncolytic virus G47D and both tumors regressed rapidly in response to direct injection of this vector. There was complete regression and no regrowth of most human HEI193 schwannomas after treatment, whereas the mouse NF2S-1 tumors resumed growth at the rate before treatment within 2 weeks after the last vector injection. This differential sensitivity of schwannomas to HSV therapy is consistent with: the higher burst size of G47D virus in HEI193 as compared to NF2S-1 cells; the faster growth rate of HEI193 tumors combined with the selectivity of G47D replication for rapidly dividing cells; and the increased susceptibility of human cells versus mouse cells to HSV-1 infection. These studies support the use of oncolytic G47D for treatment of rapidly growing schwannomas as a means of shrinking the tumor mass, while minimizing potential damage to associated nerves.
Advantages and disadvantages of current mouse models for schwannomas A number of mouse models of schwannoma have been generated which have provided insights into the etiology and pathology of these tumors based on mutations in the tumor suppressor gene, NF2.
23, 24 Giovannini et al.
10 generated transgenic mouse lines in which a dominant negative mutant form of merlin, which has been identified in some human NF2 patients, was expressed under the Schwann cell-specific P0 promoter. These transgenic mice developed Schwann cell-derived tumors between 9 and 20 months of age typically in the trigeminal ganglia, spinal ganglia and nerve endings in skeletal muscle. Based on MRI volumetric tracking of several tumors in these mice, the growth rate was estimated at about 0.5 mm 12 characterized a conditional knock-out model of NF2 (NF2floxed), which developed schwannomas, Schwann-cell hyperplasias, cataracts and osseous metaplasias when crossed with transgenic mice expressing Cre recombinase under the P0 promoter, as well as meningiomas after neonatal intraventricular injections of adenovirus encoding Cre recombinase. 13 Furthermore, introduction of hemizygosity for the tumor suppressor gene p53 in the NF2floxed Â P0-Cre mice resulted in rapid generation of malignant peripheral nerve sheath tumors by the time of death, within 2 months after birth.
14 Subcutaneous tumors have also been generated in nude mice by implantation of fragments of human schwannoma tissue (removed at surgery), albeit the success rate was only about 17% and tumors grew slowly (about 5 mm 3 /day; 15 ). The present study provides a new model of schwannomas, which are formed in nude mice by injection of schwannoma cell lines. It offers particular advantages for assessing therapeutic agents because the tumors are placed in a reproducible, accessible site, and growth/regression can be monitored over time by external caliber measurements. In addition, for the mouse schwannoma cell line studies can potentially be carried out in a syngeneic, immune competent host. Origin of mouse schwannoma It is not clear how subcutaneous implantation of human schwannoma tissue from an NF2 patient resulted in generation of a schwannoma tumor from endogenous mouse Schwann cells. It is possible that growth factors or peripheral nerve sheath damage caused by implantation of the implant resulted in dedifferentiation and proliferation of Schwann cells at that site. These endogenous Schwann cells may then have undergone genetic changes that led to continuing proliferation. Their classification as schwannoma cells is based on positive staining for S100 (immunofluorescence) and GFAP (immunohistochemistry), as well as selective activation of the P0 promoter (in preparation).
Current treatment paradigms and risk/benefit of oncolytic HSV The current treatment paradigm for human schwannomas is either surgical removal or radiosurgery, and because these tumors are benign, even reduction in tumor mass can be beneficial as there is no risk of metastasis. However, in some cases, especially cranial nerve schwannomas, resection may not be possible or may cause unacceptable damage. Therefore, oncolytic HSV vectors provide a new therapeutic option. These oncolytic vectors typically lack genes for ribonucleotide reductase and gamma 34.5 which allow them to propagate selectively in dividing cells, thereby killing them and generating more virus on site, with low toxicity to central or peripheral nerves. 18, 25, 26 The G207 HSV vector of this configuration has been tested in phase 1 clinical trials for brain tumors and found to have no serious adverse side effects. 27 The G47D vector used in the present study has the same backbone as G207, but is additionally mutated for ICP47, which blocks antigen presentation in infected cells, 28 resulting in increased antiviral and antitumor T-cell activity and enhanced propagation and therapeutic efficacy in a number of tumor cell types as compared to G207. 19, 29 Given the high infectivity of schwannomas by HSV vectors and the efficiency of oncolytic HSV in reducing tumor mass, these vectors offer a promising alternative or combinatorial therapy in treating schwannoma tumors in humans. Figure 5 Extended evaluation of G47D-treated tumors. HEI193 (a) and NF2S-1 (b) tumors were established and injected with G47D as in Figure 3 , the injections were carried out when the tumors were about 100 mm 3 in size at 7 and 10 days for HEI193 tumors and at 14 and 21 days for NF2S-1 tumors. In both cases, tumor size was reduced significantly, Po0.002 for HEI193 tumors on day 10 after initial treatment and Po0.02 for NF2S-1 tumors on day 21 after initial treatment.
